A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II)

Shiro Nozawa, Masazumi Yajima, Hirosuke Sasaki, Katsumi Tsukazaki, Daisuke Aoki, Motoko Sakayori, Yasuhiro Udagawa, Toshifumi Kobayashi, Ichiro Sato, Shoji Furusako, Hiroshi Mochizuki

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A cell line designated RMG-II was established from the ascites of a patient with ovarian clear cell carcinoma. The chromosomal analysis revealed aneuploidy with a hypertetraploid modal number and 8 marker chromosomes. Radioimmunoassay and immunocytochemical staining showed that RMG-II cells produced some tumor markers such as CA125 and TPA. Two monoclonal antibodies, designated MA602-1 and MA602-6, were generated by immunization of mice with an extract prepared from the culture supernatant of RMG-II cells. The epitopes recognized by these two monoclonal antibodies were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. We developed a double-determinant sandwich enzyme immunoassay using these two monoclonal antibodies, and the antigen defined by this assay was termed CA602. CA602 was frequently found in the sera of ovarian cancer patients; the positive rates were 92%, 38%, 60%, and 80% for serous, mucinous, clear cell, and endometrioid ovarian carcinomas, respectively, when the cut-off value was set at 60 U/ml (=mean + 3SD of healthy females). CA602 levels in serum were also high in endometriosis patients and in early pregnancy, as is the case for CA125, and the correlation coefficient between CA602 and CA125 was high (r=0.88). Our preliminary evidence suggests that this CA602 assay system has higher sensitivity than the CA125 one.

Original languageEnglish
Pages (from-to)854-861
Number of pages8
JournalJapanese Journal of Cancer Research
Volume82
Issue number7
Publication statusPublished - 1991 Jul

Fingerprint

CA-125 Antigen
Monoclonal Antibodies
Carcinoma
Cell Line
Epitopes
Endometrioid Carcinoma
Chromosomes, Human, Pair 8
Aneuploidy
Endometriosis
Tumor Biomarkers
Serum
Immunoenzyme Techniques
Genetic Markers
Ascites
Ovarian Neoplasms
Radioimmunoassay
Immunization
CA602 antigen
Staining and Labeling
Antigens

Keywords

  • CA125
  • CA602
  • Monoclonal antibodies
  • Ovarian carcinoma
  • Tumor marker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). / Nozawa, Shiro; Yajima, Masazumi; Sasaki, Hirosuke; Tsukazaki, Katsumi; Aoki, Daisuke; Sakayori, Motoko; Udagawa, Yasuhiro; Kobayashi, Toshifumi; Sato, Ichiro; Furusako, Shoji; Mochizuki, Hiroshi.

In: Japanese Journal of Cancer Research, Vol. 82, No. 7, 07.1991, p. 854-861.

Research output: Contribution to journalArticle

Nozawa, S, Yajima, M, Sasaki, H, Tsukazaki, K, Aoki, D, Sakayori, M, Udagawa, Y, Kobayashi, T, Sato, I, Furusako, S & Mochizuki, H 1991, 'A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II)', Japanese Journal of Cancer Research, vol. 82, no. 7, pp. 854-861.
Nozawa, Shiro ; Yajima, Masazumi ; Sasaki, Hirosuke ; Tsukazaki, Katsumi ; Aoki, Daisuke ; Sakayori, Motoko ; Udagawa, Yasuhiro ; Kobayashi, Toshifumi ; Sato, Ichiro ; Furusako, Shoji ; Mochizuki, Hiroshi. / A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). In: Japanese Journal of Cancer Research. 1991 ; Vol. 82, No. 7. pp. 854-861.
@article{8c2079b6145b403e9c63e54e0d211b9b,
title = "A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II)",
abstract = "A cell line designated RMG-II was established from the ascites of a patient with ovarian clear cell carcinoma. The chromosomal analysis revealed aneuploidy with a hypertetraploid modal number and 8 marker chromosomes. Radioimmunoassay and immunocytochemical staining showed that RMG-II cells produced some tumor markers such as CA125 and TPA. Two monoclonal antibodies, designated MA602-1 and MA602-6, were generated by immunization of mice with an extract prepared from the culture supernatant of RMG-II cells. The epitopes recognized by these two monoclonal antibodies were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. We developed a double-determinant sandwich enzyme immunoassay using these two monoclonal antibodies, and the antigen defined by this assay was termed CA602. CA602 was frequently found in the sera of ovarian cancer patients; the positive rates were 92{\%}, 38{\%}, 60{\%}, and 80{\%} for serous, mucinous, clear cell, and endometrioid ovarian carcinomas, respectively, when the cut-off value was set at 60 U/ml (=mean + 3SD of healthy females). CA602 levels in serum were also high in endometriosis patients and in early pregnancy, as is the case for CA125, and the correlation coefficient between CA602 and CA125 was high (r=0.88). Our preliminary evidence suggests that this CA602 assay system has higher sensitivity than the CA125 one.",
keywords = "CA125, CA602, Monoclonal antibodies, Ovarian carcinoma, Tumor marker",
author = "Shiro Nozawa and Masazumi Yajima and Hirosuke Sasaki and Katsumi Tsukazaki and Daisuke Aoki and Motoko Sakayori and Yasuhiro Udagawa and Toshifumi Kobayashi and Ichiro Sato and Shoji Furusako and Hiroshi Mochizuki",
year = "1991",
month = "7",
language = "English",
volume = "82",
pages = "854--861",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II)

AU - Nozawa, Shiro

AU - Yajima, Masazumi

AU - Sasaki, Hirosuke

AU - Tsukazaki, Katsumi

AU - Aoki, Daisuke

AU - Sakayori, Motoko

AU - Udagawa, Yasuhiro

AU - Kobayashi, Toshifumi

AU - Sato, Ichiro

AU - Furusako, Shoji

AU - Mochizuki, Hiroshi

PY - 1991/7

Y1 - 1991/7

N2 - A cell line designated RMG-II was established from the ascites of a patient with ovarian clear cell carcinoma. The chromosomal analysis revealed aneuploidy with a hypertetraploid modal number and 8 marker chromosomes. Radioimmunoassay and immunocytochemical staining showed that RMG-II cells produced some tumor markers such as CA125 and TPA. Two monoclonal antibodies, designated MA602-1 and MA602-6, were generated by immunization of mice with an extract prepared from the culture supernatant of RMG-II cells. The epitopes recognized by these two monoclonal antibodies were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. We developed a double-determinant sandwich enzyme immunoassay using these two monoclonal antibodies, and the antigen defined by this assay was termed CA602. CA602 was frequently found in the sera of ovarian cancer patients; the positive rates were 92%, 38%, 60%, and 80% for serous, mucinous, clear cell, and endometrioid ovarian carcinomas, respectively, when the cut-off value was set at 60 U/ml (=mean + 3SD of healthy females). CA602 levels in serum were also high in endometriosis patients and in early pregnancy, as is the case for CA125, and the correlation coefficient between CA602 and CA125 was high (r=0.88). Our preliminary evidence suggests that this CA602 assay system has higher sensitivity than the CA125 one.

AB - A cell line designated RMG-II was established from the ascites of a patient with ovarian clear cell carcinoma. The chromosomal analysis revealed aneuploidy with a hypertetraploid modal number and 8 marker chromosomes. Radioimmunoassay and immunocytochemical staining showed that RMG-II cells produced some tumor markers such as CA125 and TPA. Two monoclonal antibodies, designated MA602-1 and MA602-6, were generated by immunization of mice with an extract prepared from the culture supernatant of RMG-II cells. The epitopes recognized by these two monoclonal antibodies were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. We developed a double-determinant sandwich enzyme immunoassay using these two monoclonal antibodies, and the antigen defined by this assay was termed CA602. CA602 was frequently found in the sera of ovarian cancer patients; the positive rates were 92%, 38%, 60%, and 80% for serous, mucinous, clear cell, and endometrioid ovarian carcinomas, respectively, when the cut-off value was set at 60 U/ml (=mean + 3SD of healthy females). CA602 levels in serum were also high in endometriosis patients and in early pregnancy, as is the case for CA125, and the correlation coefficient between CA602 and CA125 was high (r=0.88). Our preliminary evidence suggests that this CA602 assay system has higher sensitivity than the CA125 one.

KW - CA125

KW - CA602

KW - Monoclonal antibodies

KW - Ovarian carcinoma

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0025800042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025800042&partnerID=8YFLogxK

M3 - Article

C2 - 1715339

AN - SCOPUS:0025800042

VL - 82

SP - 854

EP - 861

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -